ADYX: AI 评分 47/100 — AI 分析 (4月 2026)

Adynxx, Inc. is a clinical-stage biopharmaceutical company focused on developing transcription factor decoy technologies for pain and inflammatory diseases. Their lead candidate, brivoligide, is in Phase II clinical development for postoperative pain reduction.

Key Facts: AI Score: 47/100 Sector: Healthcare

公司概况

概要：

Adynxx, Inc. is a clinical-stage biopharmaceutical company specializing in transcription factor decoy technologies for treating pain and inflammatory diseases. Their AYX platform, including brivoligide in Phase II trials, aims to address unmet needs in postoperative and chronic pain management, positioning them within the competitive biotechnology sector.

ADYX是做什么的？

Founded in 2007 and headquartered in San Francisco, California, Adynxx, Inc. is a clinical-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for pain and inflammatory diseases. The company's core technology revolves around transcription factor decoy molecules, designed to modulate gene expression and reduce inflammation and pain signaling. Adynxx's lead product candidate, brivoligide, is an AYX platform molecule currently in Phase II clinical development for the reduction of postoperative pain. Brivoligide represents a novel approach to pain management by targeting specific transcription factors involved in the inflammatory cascade. In addition to brivoligide, Adynxx is also advancing AYX2, a pre-clinical candidate intended for the treatment of focal chronic pain. The company's focus on transcription factor decoy technology differentiates it from traditional pharmaceutical approaches, offering the potential for more targeted and effective pain management strategies. Adynxx's mission is to address the significant unmet medical needs in pain management and inflammatory diseases through the development of innovative therapies.

ADYX的投资论点是什么？

Adynxx, Inc. presents a high-risk, high-reward investment opportunity within the biotechnology sector. The company's lead candidate, brivoligide, is currently in Phase II clinical development for postoperative pain, representing a potential near-term catalyst. Success in Phase II trials could significantly increase the company's valuation. However, the company's limited financial resources, with a market cap of $0.00B and negative free cash flow, pose a significant risk. The negative beta of -6.13 suggests an inverse correlation with the market, which may or may not be desirable. Further, the biotechnology industry is inherently risky, with a high failure rate for clinical trials. The advancement of AYX2, a pre-clinical candidate for focal chronic pain, offers long-term growth potential, but is subject to significant regulatory and development hurdles.

ADYX在哪个行业运营？

Adynxx, Inc. operates within the competitive biotechnology industry, which is characterized by high research and development costs, lengthy regulatory approval processes, and a high degree of risk. The market for pain management therapies is substantial, driven by an aging population and increasing prevalence of chronic pain conditions. Adynxx's focus on transcription factor decoy technology differentiates it from companies developing traditional small molecule or biologic drugs. The company faces competition from established pharmaceutical companies and other biotechnology firms developing novel pain therapies. Success in this industry requires strong scientific expertise, effective clinical trial execution, and the ability to secure regulatory approvals and commercial partnerships.

Biotechnology

Healthcare

ADYX有哪些增长机遇？

Successful completion of Phase II clinical trials for brivoligide in postoperative pain represents a significant growth opportunity. Positive data could lead to partnerships with larger pharmaceutical companies for Phase III development and commercialization. The market for postoperative pain management is estimated to be substantial, with a growing demand for non-opioid alternatives due to the opioid crisis. Timeline: Anticipated data readout from Phase II trials within the next 12-18 months.
Advancement of AYX2, the pre-clinical candidate for focal chronic pain, into clinical development offers a long-term growth opportunity. Chronic pain affects a significant portion of the population, and there is a need for more effective and targeted therapies. Successful development of AYX2 could expand Adynxx's product pipeline and address a larger market. Timeline: IND filing and initiation of Phase I trials within the next 2-3 years.
Expansion of the AYX platform to target other inflammatory diseases represents a potential growth opportunity. Transcription factor decoy technology has broad applicability in modulating gene expression and reducing inflammation in various disease states. Adynxx could leverage its expertise to develop new therapies for conditions such as rheumatoid arthritis, inflammatory bowel disease, and psoriasis. Timeline: Identification of new targets and initiation of pre-clinical studies within the next 3-5 years.
Strategic partnerships with academic institutions or other biotechnology companies could accelerate the development and commercialization of Adynxx's technology. Collaborations could provide access to new technologies, expertise, and funding. Partnering with established players in the pharmaceutical industry could facilitate the advancement of Adynxx's product pipeline and increase its market reach. Timeline: Ongoing discussions with potential partners.
Securing additional funding through venture capital or public offerings is essential for supporting the company's clinical development programs and expanding its research and development capabilities. Access to capital will enable Adynxx to advance its product pipeline, conduct clinical trials, and build a commercial infrastructure. Timeline: Seeking funding within the next 6-12 months.

Adynxx, Inc. is a clinical-stage biopharmaceutical company focused on pain and inflammatory diseases.
The company's lead product candidate, brivoligide, is in Phase II clinical development for postoperative pain reduction.
Adynxx's technology platform is based on transcription factor decoy molecules.
The company has a pre-clinical candidate, AYX2, for the treatment of focal chronic pain.
Adynxx, Inc. has a market capitalization of $0.00B and negative free cash flow.

ADYX提供哪些产品和服务？

Develop transcription factor decoy technologies.
Focus on treatments for pain and inflammatory diseases.
Develop the AYX platform of transcription factor decoys.
Develop brivoligide for postoperative pain reduction (Phase II).
Develop AYX2 for focal chronic pain (pre-clinical).
Conduct clinical trials to evaluate the safety and efficacy of their drug candidates.

ADYX如何赚钱？

Develop novel therapies for pain and inflammatory diseases.
Out-license or partner with larger pharmaceutical companies for late-stage development and commercialization.
Generate revenue through milestone payments and royalties on partnered products.

Pharmaceutical companies seeking novel pain management therapies.
Patients suffering from postoperative pain.
Patients suffering from focal chronic pain.

Proprietary transcription factor decoy technology platform.
Patent protection for their drug candidates and technology.
Clinical data supporting the safety and efficacy of brivoligide.

什么因素可能推动ADYX股价上涨？

Upcoming: Data readout from Phase II clinical trials for brivoligide in postoperative pain.
Upcoming: IND filing and initiation of Phase I trials for AYX2 in focal chronic pain.
Ongoing: Potential partnerships with pharmaceutical companies for late-stage development and commercialization.
Ongoing: Securing additional funding through venture capital or public offerings.

ADYX的主要风险是什么？

Potential: Failure of Phase II clinical trials for brivoligide.
Potential: Regulatory delays or rejection of drug candidates.
Potential: Competition from other pain management therapies.
Ongoing: Limited financial resources and dependence on external funding.
Ongoing: High risk inherent in biotechnology drug development.

ADYX的核心优势是什么？

Novel transcription factor decoy technology.
Lead product candidate in Phase II clinical development.
Experienced management team.
Focus on unmet medical needs in pain management.

ADYX的劣势是什么？

Limited financial resources.
Dependence on a single lead product candidate.
High risk of clinical trial failure.
Small number of employees.

ADYX有哪些机遇？

Partnerships with larger pharmaceutical companies.
Expansion of the AYX platform to other inflammatory diseases.
Growing market for non-opioid pain therapies.
Positive clinical trial results.

ADYX面临哪些威胁？

Competition from established pharmaceutical companies.
Regulatory hurdles and delays.
Failure of clinical trials.
Inability to secure additional funding.

Key Metrics

MoonshotScore: 47/100

Company Profile

Headquarters: San Francisco, United States
Employees: 6

AI Insight

AI analysis pending for ADYX

OTC Tier: OTC Other
Disclosure Status: Unknown

常见问题

What does Adynxx, Inc. do?

Adynxx, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for pain and inflammatory diseases. The company's core technology revolves around transcription factor decoy molecules, designed to modulate gene expression and reduce inflammation and pain signaling. Their lead product candidate, brivoligide, is in Phase II clinical development for postoperative pain, offering a potential non-opioid alternative. Adynxx aims to address significant unmet medical needs in pain management through targeted therapies.

What do analysts say about ADYX stock?

As of March 16, 2026, there is no available analyst coverage for Adynxx, Inc. (ADYX). Given its market capitalization of $0.00B and clinical-stage status, the company may not be actively followed by major research firms. Potential investors should conduct their own due diligence and consider the inherent risks associated with investing in small-cap biotechnology companies, particularly those with limited financial resources and ongoing clinical trials. The success of brivoligide's Phase II trials will be a key factor in determining the company's future prospects.

What are the main risks for ADYX?

Adynxx, Inc. faces several key risks inherent to the biotechnology industry. The primary risk is the potential failure of its lead product candidate, brivoligide, in Phase II clinical trials. Clinical trial failures are common in biotechnology and can significantly impact a company's valuation. The company also faces regulatory risks associated with obtaining FDA approval for its drug candidates. Furthermore, Adynxx has limited financial resources and is dependent on external funding to support its clinical development programs. Competition from established pharmaceutical companies and other biotechnology firms also poses a threat.